British techbio Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of T cell receptor (TCR) therapeutics designed using generative AI. The company’s lead therapeutic programme, ETC-101, is the world’s first AI-designed bispecific T cell engager. It targets PRAME, a validated antigen present in many cancers but absent […]
